**Stratification of COVID-19 severity using SeptiCyte RAPID, a novel host immune response test.**

Victor Gravrand1, François Mellot2, Felix Ackerman3, Maric Christine Ballester4, Benjamin Zuber5, James T. Kirk6, Krupa Navalkar6, Thomas D. Yager6, Fabien Petit1, Tiffany Pascreau1,7, Eric Farfour1, Marc Vasse 1,7

1Biology Department, Foch Hospital, Suresnes, France.

2Radiology Department, Foch Hospital, Suresnes, France.

3Internal Medicine Department, Foch Hospital, Suresnes, France.

4Emergency Department, Foch Hospital, Suresnes, France.

5Intensive Care Unit, Foch Hospital, Suresnes, France.

6Immunexpress, Inc., Seattle, Washington, United States).

7UMR-S1176, Le Kremlin-Bicêtre, France.

§Corresponding author, at email address: m.vasse@hopital-foch.com

**Supplementary Tables**

Supplementary Table 1: Patient comorbidities and treatments

| Characteristic | Stratum | N (%) |
| --- | --- | --- |
| Number of comorbidities  | 5 | 1 (1.0%) |
| 4 | 5 (5.3%) |
| 3 | 13 (13.8%) |
| 2 | 30 (31.9 %) |
| 1 | 23 (24.5.0%) |
| 0 | 22 (23.4 %) |
| Types of comorbidities | None listed | 22 (23.4%) |
| Hypertension | 42 (44.7%) |
| Diabetes | 32 (34.0 %) |
| Obesity (BMI ≥ 30)\* | 22 (23.4%) |
| Pulmonary | 15 (16.0%) |
| Renal | 10 (10.6%) |
| Cardiovascular | 13 (13.8 %) |
| Cancer | 10 (10.6%) |
| Dyslipidemia | 6 (6.4 %) |
| Hypothyroidism | 5 (5.3%) |
| Treatments | ICU | 30 (31.9%) |
| Corticosteroids | 51 (54.3%) |
| Tocilizumab | 24 (25.5 %) |
| Oxygen | 57 (60.6%) |
| Intubation | 7 (7.4%) |
| ECMO | 3 (3.2%) |
| Antibiotics | 36 (38.3%) |

\*BMI available for only 46 patients

Supplementary Table 2 : Distribution of SARS-CoV-2 (+) patients across COVID-19 severity categories and hospital locations. COVID-19 severity assessments were made on the basis of chest CT scans, conducted within 24 hours of SeptiCyte RAPID measurement. Range is specified in [ ] square brackets, and percentage is specified in ( ) parentheses. The median values for age and the median time between onset of symptoms and SeptiCyte result are reported for those patients with CT scan results.

|  | Emergency Department (Fig 1a) (n=67 total; 49 with CT scan results) | ICU (Fig 1b) | Conventional Unit,Viremia(Fig. 1c) |
| --- | --- | --- | --- |
| Follow-up | Discharged (< 24 hours in ED) | ConventionalHospitalization | Delayed ICU admission | Immediate ICU admission | Deceased in ED |  |  |
| n (total) = 94 | 25 | 33 | 4 | 3 | 2 | 23 | 4 |
| n (with CT scan result) | 12 | 30 | 4 | 2 | 1 | 15 | 4 |
| F/M (with CT scan result) | 6/6 | 13/17 | 2/2 | 0/2 | 1/0 | 6/9 | 1/3 |
| Median age, years | 58[20 – 84] | 71[23 – 96] | 66[63 – 66] | 77[76 – 78] | >80 | 59[27 – 78] | 57[38 – 67] |
| Median time between onset of symptoms andSeptiCyte result, days (symptomatic patients)  | 7 (n=11)[1 – 12] | 7 (n=28)[0 – 30] | 6 (n=4)[4 – 9] | 8.5 (n=2)[7 – 10] | NA | 10[1 – 24] | 9[9 – 11] |
| Radiologic injury, n (%) |  |  |  |  |  |  |  |
| Absence (0%) | 5 (20%) | 1 (3%) | 0 | 0 | 0 | 0 | 0 |
| Mild (present but <10 %) | 1 (4%) | 8 (24%) | 0 | 0 | 0 | 0 | 1 (25%) |
| Moderate [10 – 25 %] | 4 (16%) | 8 (24%) | 1 (25%) | 0 | 1 (50%) | 2 (8.7%) | 1 (25%) |
| Extensive (25 - 50 %) | 1 (4%) | 11 (33%) | 1 (25%) | 1 (33.3%) | 0 | 4 (17%) | 2 (50%) |
| Severe [50 – 75 %] | 0 | 1 (3%) | 1 (25%) | 1 (33.3%) | 0 | 6 (26%) | 0 |
| Critical (> 75 %) | 0 | 0 | 0 | 0 | 0 | 3 (13.1%) | 0 |
| Not specific | 1 (4%) | 1 (3%) | 1 (25%) | 0 | 0 | 0 | 0 |
| Not performed | 13 (52%) | 3 (9.1%) | 0 | 1 (33.3%) | 1 (50%) | 8 (34.8%) | 0 |

Supplementary Table 3: Logistic Regression models (see Figs. 4A, 4B in main text). A complete permutation analysis of different logistic combinations of up to six variables (SeptiScore, monocytes, CD16-monocytes, D-dimer, lactate and CRP) was conducted, resulting in 63 independent logistic regression models. The models were used to discriminate Critical + Severe in ICU (n=13) vs. Moderate + Mild not in ICU (n = 24) and their AUC values were calculated. Interquartile ranges for AUC were obtained by resampling from 100 replicate datasets. Missing values in the line data were imputed using Amelia, a multiple imputation algorithm [1]. Multiple imputation is claimed to have reduced bias and increased accuracy over point-imputation methods such as "mean" or "median" imputation [1]. (The numbers of missing values were 1 for monocytes; 7 for CD16-monocytes, 9 for D-dimer; 11 for lactate; and 1 for CRP.) Abbreviations: CRP, C-reactive protein; Mono, monocytes; Mono.CD16, CD16-monocytes.

| **Model** | **variables** | **MEAN** | **MEDIAN** | **25%** | **75%** |
| --- | --- | --- | --- | --- | --- |
| 1 | CRP | 0.867 | 0.871 | 0.860 | 0.890 |
| 2 | D-dimer | 0.630 | 0.640 | 0.576 | 0.679 |
| 3 | Lactate | 0.668 | 0.680 | 0.607 | 0.729 |
| 4 | Mono | 0.725 | 0.722 | 0.703 | 0.748 |
| 5 | Mono.CD16 | 0.750 | 0.752 | 0.698 | 0.791 |
| 6 | D-dimer + Lactate | 0.663 | 0.674 | 0.613 | 0.724 |
| 7 | Lactate + Mono | 0.739 | 0.742 | 0.716 | 0.761 |
| 8 | D-dimer + Lactate + Mono | 0.767 | 0.765 | 0.739 | 0.792 |
| 9 | Mono + Mono.CD16 | 0.768 | 0.758 | 0.734 | 0.807 |
| 10 | D-dimer + Mono | 0.769 | 0.769 | 0.742 | 0.792 |
| 11 | Lactate + Mono.CD16 | 0.779 | 0.778 | 0.730 | 0.838 |
| 12 | Lactate + Mono + Mono.CD16 | 0.792 | 0.780 | 0.745 | 0.837 |
| 13 | D-dimer + Mono.CD16 | 0.811 | 0.811 | 0.773 | 0.845 |
| 14 | D-dimer + Mono + Mono.CD16 | 0.824 | 0.822 | 0.792 | 0.864 |
| 15 | D-dimer + Lactate + Mono.CD16 | 0.831 | 0.831 | 0.779 | 0.875 |
| 16 | D-dimer + Lactate + Mono + Mono.CD16 | 0.839 | 0.841 | 0.798 | 0.880 |
| 17 | CRP + D-dimer | 0.866 | 0.867 | 0.856 | 0.887 |
| 18 | CRP + Mono | 0.872 | 0.883 | 0.855 | 0.894 |
| 19 | CRP + Lactate | 0.872 | 0.875 | 0.860 | 0.890 |
| 20 | CRP + D-dimer + Lactate | 0.874 | 0.875 | 0.864 | 0.890 |
| 21 | CRP + Lactate + Mono | 0.875 | 0.883 | 0.860 | 0.894 |
| 22 | CRP + D-dimer + Mono | 0.883 | 0.886 | 0.864 | 0.902 |
| 23 | CRP + D-dimer + Lactate + Mono | 0.886 | 0.888 | 0.867 | 0.902 |
| 24 | CRP + Mono.CD16 | 0.888 | 0.890 | 0.867 | 0.910 |
| 25 | CRP + Mono + Mono.CD16 | 0.893 | 0.890 | 0.874 | 0.913 |
| 26 | CRP + Lactate + Mono.CD16 | 0.895 | 0.894 | 0.871 | 0.913 |
| 27 | CRP + D-dimer + Mono.CD16 | 0.896 | 0.896 | 0.871 | 0.920 |
| 28 | CRP + Lactate + Mono + Mono.CD16 | 0.899 | 0.898 | 0.883 | 0.920 |
| 29 | CRP + D-dimer + Lactate + Mono.CD16 | 0.900 | 0.898 | 0.878 | 0.924 |
| 30 | CRP + D-dimer + Mono + Mono.CD16 | 0.903 | 0.905 | 0.886 | 0.929 |
| 31 | CRP + D-dimer + Lactate + Mono + Mono.CD16 | 0.910 | 0.909 | 0.890 | 0.932 |
| 32 | SeptiScore | 0.888 | 0.888 | 0.888 | 0.888 |
| 33 | SeptiScore + D-dimer | 0.893 | 0.890 | 0.886 | 0.898 |
| 34 | SeptiScore + Lactate | 0.895 | 0.894 | 0.886 | 0.902 |
| 35 | SeptiScore + Mono | 0.896 | 0.898 | 0.883 | 0.906 |
| 36 | SeptiScore + D-dimer + Mono | 0.900 | 0.900 | 0.890 | 0.905 |
| 37 | SeptiScore + CRP | 0.901 | 0.913 | 0.883 | 0.917 |
| 38 | SeptiScore + D-dimer + Lactate | 0.903 | 0.898 | 0.890 | 0.909 |
| 39 | SeptiScore + CRP + Lactate | 0.905 | 0.911 | 0.886 | 0.920 |
| 40 | SeptiScore + Lactate + Mono | 0.906 | 0.909 | 0.893 | 0.917 |
| 41 | SeptiScore + CRP + D-dimer | 0.912 | 0.917 | 0.902 | 0.924 |
| 42 | SeptiScore + D-dimer + Lactate + Mono | 0.914 | 0.909 | 0.902 | 0.924 |
| 43 | SeptiScore + CRP + Mono | 0.915 | 0.913 | 0.905 | 0.924 |
| 44 | SeptiScore + CRP + D-dimer + Lactate | 0.915 | 0.920 | 0.902 | 0.925 |
| 45 | SeptiScore + CRP + Lactate + Mono | 0.920 | 0.924 | 0.905 | 0.932 |
| 46 | SeptiScore + CRP + D-dimer + Mono | 0.924 | 0.922 | 0.909 | 0.936 |
| 47 | SeptiScore + Mono.CD16 | 0.925 | 0.920 | 0.898 | 0.951 |
| 48 | SeptiScore + Mono + Mono.CD16 | 0.929 | 0.924 | 0.905 | 0.952 |
| 49 | SeptiScore + CRP + D-dimer + Lactate + Mono | 0.930 | 0.932 | 0.913 | 0.943 |
| 50 | SeptiScore + Lactate + Mono.CD16 | 0.933 | 0.932 | 0.902 | 0.958 |
| 51 | SeptiScore + CRP + Mono.CD16 | 0.939 | 0.939 | 0.920 | 0.962 |
| 52 | SeptiScore + Lactate + Mono + Mono.CD16 | 0.939 | 0.943 | 0.917 | 0.962 |
| 53 | SeptiScore + D-dimer + Mono.CD16 | 0.942 | 0.943 | 0.923 | 0.963 |
| 54 | SeptiScore + CRP + Lactate + Mono.CD16 | 0.943 | 0.943 | 0.920 | 0.966 |
| 55 | SeptiScore + CRP + Mono + Mono.CD16 | 0.944 | 0.943 | 0.924 | 0.967 |
| 56 | SeptiScore + D-dimer + Mono + Mono.CD16 | 0.946 | 0.947 | 0.924 | 0.970 |
| 57 | SeptiScore + CRP + Lactate + Mono + Mono.CD16 | 0.948 | 0.947 | 0.931 | 0.970 |
| 58 | SeptiScore + D-dimer + Lactate + Mono.CD16 | 0.952 | 0.955 | 0.932 | 0.973 |
| 59 | SeptiScore + CRP + D-dimer + Mono.CD16 | 0.952 | 0.951 | 0.936 | 0.973 |
| 60 | SeptiScore + D-dimer + Lactate + Mono + Mono.CD16 | 0.956 | 0.955 | 0.932 | 0.974 |
| 61 | SeptiScore + CRP + D-dimer + Lactate + Mono.CD16 | 0.956 | 0.955 | 0.939 | 0.973 |
| 62 | SeptiScore + CRP + D-dimer + Mono + Mono.CD16 | 0.956 | 0.955 | 0.936 | 0.973 |
| 63 | SeptiScore + CRP + D-dimer + Lactate + Mono + Mono.CD16 | 0.961 | 0.962 | 0.942 | 0.978 |

**Reference**

1. Honaker, J., King, G., & Blackwell, M. Amelia II: A Program for Missing Data. *J. Statistical Software* **45**(7), 1–47 (2011).